Inogen, Inc. Q3 FY2025 earnings call

• Driving top line growth: Seventh consecutive mid-single-digit revenue growth, over $92M revenue; unit growth of >15% in POCs; domestic B2B 7% y-o-y growth; international B2B 19% y-o-y growth.
• Advancing profitability: Operating expenses down 1.4% y-o-y; adjusted EBITDA $2.3M, third consecutive adjusted EBITDA profit.
• Innovation pipeline: Launch of Voxi 5, a stationary oxygen concentrator; limited market release of Simeox in US for bronchial decongestion, laying groundwork for commercialization.

Total revenue for the third quarter of 2025 was $92.4 million. Domestic B2B revenue increased 6.6% to $24.9 million versus the prior period. International B2B revenue increased 18.8% to $38.4 million. Direct-to-consumer sales decreased 17.9% to $15.8 million. Rental revenue decreased 4.4% to $13.3 million. Domestic B2B contributed 6.6% to revenue growth, international B2B 18.8%, direct-to-consumer and rental had negative contributions.

• Full year revenue guidance: $354M-$357M (6% y-o-y midpoint). - Adjusted EBITDA raised to ~$2M for full year 2025. - Q4 revenue expected: $87M-$90M (10% midpoint y-o-y growth).

• Tariffs: No material impact expected but will closely monitor developments. - DTC business: Timing of stabilization could affect results. - Simeox: Reimbursement and commercialization uncertainties for broad launch.

Q: Could you provide color on international B2B growth, market dynamics in POCs internationally, and international expansion plans?

A: International B2B growth is from growing share and expanding in existing and new markets; POCs have significant opportunity globally; new markets like China are in progress.

Q: Can you share updates on Voxi 5 sales and timing?

A: Voxi 5 has initial sales, but material impact yet; more impact expected in 2026.

Q: What's driving rental gross margin decline and future margin pressure?

A: Main driver was a logistic trough adjustment; headwinds from Medicare reimbursement and capped patients, but some stabilization.

Q: Update on Simeox reimbursement progress and commercial launch timing?

A: Progress in European and Chinese trials, limited market release in US; positive feedback, but specific timeline not guided yet